Biotechnology Market: Surging Investments and Infrastructure Development Propel 13.9% CAGR by 2031| SkyQuest Technology
Insiders At Adaptive Biotechnologies Sold US$664k In Stock, Alluding To Potential Weakness
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor
Express News | Adaptive Biotechnologies Says Its Next-generation Sequencing-based ClonoSEQ Test For Measurable Residual Disease Assessment Will Be Included In Several Oral And Poster Presentations At American Society Of Clinical Oncology Annual Meeting
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment With ClonoSEQ To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 50% Higher
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Warby Parker (WRBY) and Adaptive Biotechnologies (ADPT)
Why Adaptive Biotechnologies Topped the Market Today
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2024 Earnings Call Transcript
Earnings Call Summary | Adaptive Biotechnologies(ADPT.US) Q1 2024 Earnings Conference
Express News | Adaptive Biotechnologies Corp : Btig Raises Target Price to $6 From $5
Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT), Veracyte (VCYT) and Nevro Corp (NVRO)
Analysts Offer Insights on Healthcare Companies: Clover Health Investments (CLOV), Cogent Biosciences (COGT) and Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies Corp (ADPT) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Compared to Estimates, Adaptive Biotechnologies (ADPT) Q1 Earnings: A Look at Key Metrics
Adaptive Biotechnologies Q1 Loss Decreases, Beats Estimates
Adaptive Biotechnologies | 10-Q: Quarterly report
Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q1 Revenue $41.9M, Vs. Street Est of $38.8M
No Data